stockrow
Saturday 7 November 2026
Export OMER’s income statement to Excel — free account
Omeros Corporation
OMER Healthcare Biotechnology
- Revenue
- +35.5%
- EPS
- +141.9%
- Free cash flow
- +118.7%
- Total debt
- −42.0%
Quarter to June 2026, against a year earlier
16.83
0.24
−1.41%
Follow OMER
Alert me
Omeros Corporation (OMER) P/E ratio
As of 6 November 2026, Omeros Corporation (OMER) trades at a P/E ratio of 9.8×. Over the past ten years it has ranged from 0.0× (March 2026) to 13.7× (May 2026); the current reading is higher than 97% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 5.6× | (42.07%) |
| Mar 2026 | 9.6× | — |
| Sep 2021 | 0.0× | — |
| Jun 2021 | 0.0× | — |
| 25 more quarters | Free account |
Against its own ten years
Low 0.0×
High 13.7×
Ten-year median
0.0×
Current reading's percentile
97
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NKTR Nektar Therapeutics compare | n/m |
| DRTS Alpha Tau Medical Ltd. compare | n/m |
| MNKD MannKind Corporation compare | n/m |
| URGN Urogen Pharma compare | n/m |
| SLN Silence Therapeutics PLC Sponsored ADR compare | n/m |
| GHRS GH Research PLC compare | n/m |
| LBRX LB Pharmaceuticals Inc compare | n/m |
| KARD KARDIGAN INC compare | n/m |
| OMER Omeros Corporation | 9.8× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)